

11<sup>th</sup> November 2025  
IOLCP/CGC/2025

**National Stock Exchange of India Ltd**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**Security Symbol: IOLCP**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

**Security Code: 524164**

**Subject: Press Release – Financial Results for the quarter and half year ended 30<sup>th</sup> September 2025**

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 11<sup>th</sup> November 2025 with respect to financial results for the quarter and half year ended 30<sup>th</sup> September 2025.

Hope you will find the same in order.

Thanking You,

Yours faithfully,  
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh  
Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited

## IOL Chemicals and Pharmaceuticals Limited Reports Q2 & H1 FY26 Results

*Delivers Strong Performance with Margin Expansion and Strategic Progress*

**Ludhiana, 11<sup>th</sup> November 2025:** IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Bulk Drugs & Specialty Chemicals announced its Financial Results for the quarter and half year ended 30<sup>th</sup> September 2025.

### Q2 FY26 Financial Performance Snapshot (Y-o-Y)

(Standalone)

Revenue from Operations	EBITDA	Profit After Tax
₹ 567.5 Cr	₹ 64.0 Cr	₹ 30.0 Cr
▲ 7.9%	▲ 33.3%	▲ 56.7%


### Key Standalone Financial Highlights

Particulars (₹ Cr)	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
Revenue from Operations	567.5	525.8	7.9%	1,119.2	1,028.1	8.9%
EBITDA	64.0	48.0	33.3%	133.5	106.2	25.7%
EBITDA Margin (%)	11.1%	9.0%	+212 bps	11.8%	10.2%	+159 bps
Profit After Tax	30.0	19.2	56.7%	64.0	48.8	31.0%
PAT Margin (%)	5.2%	3.6%	+162 bps	5.6%	4.7%	+96 bps
Cash Profit After Tax*	51.5	39.3	31.1%	106.3	86.6	22.9%

\* Profit Before Tax + Depreciation - Current Tax

### Segment Highlights

(In ₹ Cr)





## Q2 FY26 Business Highlights

- Received **EDQM's Certificate of Suitability** for **Pantoprazole Sodium Sesquihydrate Process-III** on **14th October 2025**, enabling exports to Europe and CEP-compliant markets. Pantoprazole sodium is a proton pump inhibitor (PPI) that reduces stomach acid and is used to treat conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
- **Incorporated IOL Pharmaxis UK Limited** in **October 2025** to strengthen international operations in Pharmaceuticals and Chemicals business and expanding its global reach.

**Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,**

*“Q2 FY26 reflects IOL's continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% year-on-year. Importantly, EBITDA margin improved to 11.1% from 9.1%, driven by better operating leverage and cost efficiencies.*

*Profit After Tax increased 56.7% year-on-year with PAT margin expanding to 5.2% from 3.6%, underscoring the strength of our integrated model. However, PAT was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs.*

*Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs.*



*We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.”*

## About IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world's largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP's API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.



## Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre <a href="mailto:prachi.ambre@in.mpms.mufg.com">prachi.ambre@in.mpms.mufg.com</a>
Mr. Abhay Raj Singh Sr. VP & Company Secretary <a href="mailto:investor@iolcp.com">investor@iolcp.com</a>	Mr. Irfan Raeen <a href="mailto:irfan.raeen@in.mpms.mufg.com">irfan.raeen@in.mpms.mufg.com</a>
	Meeting Request <a href="#">Link</a> Website: <a href="https://in.mpms.mufg.com/">https://in.mpms.mufg.com/</a>

## Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.